The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Challenging Cases in Osteoporosis: Tips from an Expert

Challenging Cases in Osteoporosis: Tips from an Expert

June 18, 2022 • By Samantha C. Shapiro, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Dr. Saag was careful to remind us that fracture risk does begin to increase the longer the time off therapy. Example: Discontinuing alendronate or risedronate for more than two years was associated with increased risk of hip and clinical vertebral fractures in a large observational cohort study of Medicare patients who had been taking bisphosphonates for at least three years.4

You Might Also Like
  • Amgen, UCB Say Osteoporosis Drug Meets Main Goal in Late-Stage Trial
  • Novel Bone Drug Promising in Postmenopausal Osteoporosis
  • At Least 1 Year on Bisphosphonates Needed for Fracture Prevention
Explore This Issue
July 2022
Also By This Author
  • How to Recognize an Autoinflammatory Disorder

“Remember, it’s just a holiday,” he said. “It’s not a complete cessation of therapy. Osteoporotic risk goes up after two years off therapy, and just how much depends on what bisphosphonate [the patient] took before. Some bisphosphonates are stickier to bone than others. Risedronate is the least sticky.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

If you aren’t certain whether a drug holiday is appropriate for your patient, the American Society for Bone and Mineral Research Algorithm for Management of Postmenopausal Women on Long Term Bisphosphonate Therapy may help. Of note, the suggested approach is “based on limited evidence, only for vertebral fracture reduction, in mostly white postmenopausal women and does not replace the need for clinical judgment. It may be applicable to men and patients with glucocorticoid-induced osteoporosis, with some adaptations.”5

In this patient’s case, a holiday was deemed appropriate given improved hip BMD with a T-score greater than or equal to -2.5, no interval fractures and Asian ethnicity conferring a higher risk of adverse events with continued bisphosphonate therapy.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Case 2

A 92-year-old woman with a history of chronic kidney disease (CKD), with glomerular filtration rate (GFR) of 32, and bilateral sacral alar fractures presented to establish care. In the past, she took alendronate, but had been off therapy for many years. Recent DXA revealed a T-score of -3.4 at the femoral neck. Metabolic bone evaluation was notable for a slightly low parathyroid hormone and slightly elevated alkaline phosphatase, consistent with remodeling of recent pelvic fractures. Calcium, phosphorous and 25-hydroxy vitamin D levels were normal.

In this case, Dr. Saag preferred either a parathyroid hormone analog, such as teriparatide or abaloparatide, or romosozumab because the patient was at very high fracture risk. In the Vertebral Fracture Comparisons in Severe Osteoporosis trial, the first active comparator study examining a parathyroid hormone analog (i.e., teriparatide) and bisphosphonate (i.e., risedronate) in a high-risk population, teriparatide conferred a significant risk reduction in people who previously had a major fracture.6

When it comes to parathyroid hormone analogs, clinicians must be aware of a few issues. Parathyroid hormone analogs may cause hypercalcemia, flushing and/or myalgia and arthralgia. The black box warning for osteosarcoma has been removed from both drugs given longitudinal experience, but they should be avoided in patients with a history of skeletal malignancies, bone metastases or skeletal radiation for this reason. Unfortunately, out-of-pocket cost remains prohibitive for many patients, which was also true for this patient. Thus, Dr. Saag opted for treatment with romosozumab followed by denosumab.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Education & Training, Meeting Reports Tagged With: ACR Education Exchange, bisphosphonates, denosumab, education and training, Osteoporosis, romosozumabIssue: July 2022

You Might Also Like:
  • Amgen, UCB Say Osteoporosis Drug Meets Main Goal in Late-Stage Trial
  • Novel Bone Drug Promising in Postmenopausal Osteoporosis
  • At Least 1 Year on Bisphosphonates Needed for Fracture Prevention
  • A Balancing Act: Tips to Ensure Optimal Screening & Treatment for Osteoporosis

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)